Reactome | IgE binds omalizumab

IgE binds omalizumab

Stable Identifier

R-HSA-9724685

Type

Reaction [binding]

Species

Homo sapiens

Compartment

extracellular region

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

General

SBML | | PDF

SVG | | PPTX | SBGN

Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

When bound to the high-affinity IgE receptor (FCERI), IgE acts as an environmental sensor that detects allergens and induces allergic responses from the cell's interior. Omalizumab is a monoclonal antibody that binds free IgE preventing it from binding to FCERI. Moreover, reduction of free IgE concentrations reduce FCERI expression level. Omalizumab is approved for the treatment of patients with severe allergic asthma. Use of omalizumab is associated with several side effects, including injection site reactions, viral and upper respiratory tract infections, headache, sinusitis, and pharyngitis. The main severe adverse effect is anaphylactic shock, with a rate of occurrence of 1 to 2 patients per 1,000 (Davydov 2005, Arm et al. 2014).

Literature References

PubMed ID	Title	Journal	Year
15686303	Omalizumab (Xolair) for treatment of asthma Davydov, L	Am Fam Physician	2005
25200415	Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects Maahs, S, Floch, D, Bottoli, I, Lowe, PJ, Owen, CE, Groenewegen, A, Skerjanec, A, Jones, I, Arm, JP	Clin. Exp. Allergy	2014